PROTACs Targeting MLKL Protect Cells from Necroptosis

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Mixed Lineage Kinase domain-Like pseudokinase (MLKL) is a key effector in necroptosis, a regulated cell death pathway implicated in various diseases.
• MLKL's central role makes it a significant target for therapeutic intervention.
• Developing chemical methods to modulate MLKL activity is crucial for disease treatment.

Purpose of the Study:

• To develop novel PROteolysis TArgeting Chimeras (PROTACs) for targeted degradation of MLKL.
• To investigate the efficacy of MLKL degradation in abrogating necroptosis.
• To explore the quantitative relationship between MLKL levels and necroptosis.

Main Methods:

• Synthesis of a series of PROTAC molecules utilizing a high-affinity pyrazole carboxamide-based MLKL ligand.
• Testing PROTAC efficacy in degrading MLKL and inhibiting cell death in a TSZ model of necroptosis.
• Dose-dependent analysis of MLKL degradation and its impact on necroptosis.

Main Results:

• Identification of a potent PROTAC molecule capable of effectively degrading MLKL.
• Complete abrogation of necroptosis in a cellular model using the developed PROTAC.
• Demonstration of a dose-dependent relationship between MLKL levels and necroptosis.

Conclusions:

• PROTAC technology provides a feasible and effective strategy for targeting MLKL.
• The developed PROTACs serve as valuable tools for studying MLKL's role in necroptosis.
• This approach holds promise for developing new therapies for diseases involving necroptosis.